The identification of pathological mechanisms underlying to Alzheimer's disease is of great importance for the discovery of potential markers for diagnosis and disease monitoring. In this study, we investigated regional metabolic alterations in brain from the APP/PS1 mice, a transgenic model that reproduces well some of the neuropathological and cognitive deficits observed in human Alzheimer's disease. For this purpose, hippocampus, cortex, cerebellum and olfactory bulbs were analyzed using a high-throughput metabolomic approach based on direct infusion mass spectrometry. Metabolic fingerprints showed significant differences between transgenic and wild-type mice in all brain tissues, being hippocampus and cortex the most affected regions. Alterations in numerous metabolites were detected including phospholipids, fatty acids, purine and pyrimidine metabolites, acylcarnitines, sterols and amino acids, among others. Furthermore, metabolic pathway analysis revealed important alterations in homeostasis of lipids, energy management, and metabolism of amino acids and nucleotides. Therefore, these findings demonstrate the potential of metabolomic screening and the use of transgenic models for understanding pathogenesis of Alzheimer's disease.
Introduction
Numerous transgenic mouse models of Alzheimer's disease (AD) have been developed for understanding disease pathology and testing potential therapies. The ideal model should show the full range of clinical and pathological features associated with AD, including cognitive and behavioral deficits, amyloid plaques, neurofibrillary tangles and neurodegeneration [1] . However, no existing model exhibits all these features, but each one has unique pathologies that provide insights into disease mechanisms. One of the models most extensively used is the double transgenic line APP/PS1, expressing the Swedish mutation of ␤-amyloid precursor protein together with deleted presenilin 1 in exon 9, which reproduces well some of the neuropathological and cognitive deficits observed in AD, with a phenotype characterized by early amyloid deposits and behavioral impairment [2] . Behavioral assessments have been traditionally used to confirm cognitive deficits in these transgenic animals [3] , but they are tedious and may suffer from high individual variability. Thus, the pathophysiological status of these models is better evaluated by analysis of brain tissue samples to detect possible biomarkers. In this context, metabolomics may present a high potential for identifying neurochemical changes involved in pathological mechanisms occurring in AD, since provides a comprehensive overview of the status of organism reflecting the interactions between genes, proteins and the environment [4] . Non-invasive metabolic profiling by means of in vivo magnetic resonance spectroscopy (MRS) has been widely applied to AD studies in different transgenic models [5] [6] [7] . The most consistent findings observed using this approach are the decrease of N-acetyl aspartate (NAA) levels, a biomarker for neuronal integrity, and the increase of myo-inositol (mIns), which is thought to be a marker for osmotic stress or astrogliosis. Additionally, changes in other metabolites such as glutamate, creatine and choline-containing compounds were also found. On the other hand, in vitro nuclear magnetic resonance (NMR)-based metabolomic investigations of postmortem brain have been also proposed, providing a wider range of measurable metabolites compared to in vivo MRS [8] [9] [10] . However, the characterization of regional metabolomic perturbations instead of overall brain changes may be of greater interest in order to investigate the impact of disease on different brain regions and determine the most affected ones in AD-mice. In this sense, only a few authors have previously performed a comparative metabolomic study in different brain regions using NMR, demonstrating that the hippocampus and temporal cortex are the most sensitive regions to disease, but other tissues are also affected such as cerebellum and midbrain [11] [12] [13] . Nevertheless, only medium to high abundance metabolites are detected with this approach and the identification of individual metabolites is challenging in complex mixtures, so very limited metabolic information can be obtained [14] . By contrast, mass spectrometry offers higher sensitivity and selectivity, and the potential to identify and quantify compounds. The combination of mass spectrometry with separation techniques is frequently reported in order to obtain simpler spectra and facilitate the interpretation of metabolic fingerprints. In this sense, different approaches based on liquid or gas chromatography coupled to mass spectrometry have been previously described for the characterization of metabolomic signatures associated with AD in brain from transgenic mice [15] [16] [17] [18] . Alternatively, metabolomics based on direct infusion mass spectrometry (DIMS) has proved to be a useful screening tool due to its wide metabolome coverage and fast analysis, despite having several drawbacks such as the lack of resolution for isobars differentiation and difficulty of quantification without stable-isotope internal standards [19] . However, this high-throughput approach is not as widespread as hyphenated techniques in routine metabolomic studies, and it was only previously applied twice to address metabolic changes in hippocampus [20] and cerebellum [21] of the CRND8 transgenic mice.
This work considers the application for the first time of direct infusion electrospray mass spectrometry for the study of metabolic abnormalities in different brain regions of the APP/PS1 transgenic mice, including cortex, hippocampus, cerebellum and olfactory bulbs. Multivariate statistics demonstrated the potential of this high-throughput fingerprinting tool for the discrimination between transgenic animals and wild-type controls, and indicated that pathological processes are widespread and not only affect to hippocampus and cortex, primary targets in Alzheimer's disease. Numerous metabolites were identified as potential markers of ADtype disorders in these mice, which may contribute to deepen into underlying pathological mechanisms related to neurodegenerative processes.
Materials and methods

Animal handling
Transgenic APP/PS1 mice (C57BL/6 background) were generated as previously described by Jankowsky et al. [22] , expressing the Swedish mutation of APP together with PS1 deleted in exon 9. On the other hand, age-matched wild-type mice of the same genetic background (C57BL/6) were purchased from Charles River Laboratory for their use as controls. In this study, male and female animals at 6 months of age were used for experiments (TG: N = 30, male/female 13/17; WT: N = 30, male/female 15/15). Animals were acclimated for 3 days after reception in rooms with a 12-h light/dark cycle at 20-25 • C, with water and food available ad libitum. Then, mice were anesthetized by isoflurane inhalation and sacrificed by exsanguination via cardiac puncture. Brains were rapidly removed, rinsed with saline solution (0.9% NaCl w/v) and dissected into hippocampus, cortex, cerebellum and olfactory bulbs. Finally, tissues were transferred to individual Eppendorf tubes, snap-frozen in liquid nitrogen and stored at −80 • C until analysis. Animals were handled according to the directive 2010/63/EU stipulated by the European Community, and the study was approved by the Ethical Committee of University of Huelva.
Tissue extraction
Large brain regions (cortex and cerebellum) were cryohomogenized using a cryogenic homogenizer SPEX SamplePrep (Freezer/Mills 6770), during 30 s at rate of 10 strokes per second. Then, tissues were extracted with pre-cooled 0.1% formic acid in methanol (−20 • C) using a pellet mixer for cell disruption (VWR International, UK). For this, tissue samples were exactly weighed in Eppendorf tubes (30 mg for homogenized tissues, and the entire organ for hippocampus and olfactory bulbs) and mixed with the extraction solvent (10 L/mg). The mixture was homogenized during 2 min in an ice bath, and then centrifuged at 10,000 rpm for 10 min at 4 • C. Finally, supernatant was taken for direct analysis. Furthermore, quality control (QC) samples were prepared by pooling equal volumes of each sample, which allows monitoring the stability and performance of the system along the analysis period [23] .
Metabolomic analysis
Mass spectrometry experiments were performed in a quadrupole-time-of-flight mass spectrometry system (QTOF-MS), model QSTAR XL Hybrid system (Applied Biosystems, Foster City, CA, USA), using the electrospray (ESI) source. Samples were directly introduced into the mass spectrometer using an integrated apparatus pump and a 1000 L volume Hamilton syringe at 5 L min −1 flow rate. Data were obtained in both positive and negative ionization modes, acquiring full scan spectra for 0.2 min in the m/z range 50-1100 with 1.005 s scan time. In positive mode, the ion spray voltage (IS) was set at 3300 V, and high-purity nitrogen was used as curtain and nebulizer gas at flow rates about 1.13 L min −1 and 1.56 L min −1 , respectively. The source temperature was fixed at 60 • C, with a declustering potential (DP) of 60 V and a focusing potential (FP) of 250 V. For ESI(−) only few parameters were modified respect ESI(+) method, with an ion spray voltage at −4000 V, a declustering potential (DP) of −100 V and a focusing potential (FP) of −250 V. To acquire MS/MS spectra, nitrogen was used as collision gas.
Data analysis
Metabolomic data were submitted to peak detection by Markerview TM software (Applied Biosystems) in order to filter the mass spectrometry results, and to carry out the reduction into a two-dimensional data matrix of spectral peaks and their intensities. For this, all peaks above the noise level (10 counts, determined empirically from experimental spectra) were selected and binned in intervals of 0.1 Da. Finally, data were normalized according to the total area sum. Then, data were subjected to multivariate analysis by principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA) in order to compare metabolomic profiles obtained, using the SIMCA-P TM software (version 11.5, UMetrics AB, Umeå, Sweden). Before performing statistical analysis, data are usually scaled and transformed in order to minimize the technical variability between individual samples to extract the relevant biological information from these data sets [24] . For this, data was submitted to Pareto scaling, for reducing the relative importance of larger values, and logarithmic transformation, in order to approximate a normal distribution. Quality of the models was assessed by the R 2 and Q 2 values, supplied by the software, which provide information about the class separation and predictive power of the model, respectively. These parameters are ranged between 0 and 1, and they indicate the variance explained by the model for all the data analyzed (R 2 ) and this variance in a test set by cross-validation (Q 2 ). In addition, these models were validated using permutation tests (Y-scrambling) of the Y-predicted values. In Y-scrambling, class labels are randomly permuted for refitting a new model with the same number of components as the original one, and then these new models are compared with the original models to test the possibility that the original model arose by chance. Thus, an overfitted model will have similar R 2 and Q 2 to that of the randomly permuted data, while well fitted and meaningful models will have R 2 and Q 2 values higher than that of the permuted data. Finally, potential biomarkers were selected according to the Variable Importance in the Projection (VIP: a weighted sum of squares of the PLS weight, which indicates the importance of the variable in the model) with confidence intervals derived from jack-knifing. Only variables with VIP values higher than 1.5 were considered, indicative of significant differences among groups. These metabolites were validated by t-test with Bonferroni correction for multiple testing (p-values below 0.05), using the STATISTICA 8.0 software (StatSoft, Tulsa, USA).
Metabolites identification
Potential biomarkers were identified matching the experimental accurate mass and tandem mass spectra (MS/MS) with those available in metabolomic databases (HMDB, METLIN and LIPIDMAPS). Furthermore, different classes of lipids were confirmed based on characteristic fragmentation patterns previously described. Phosphatidylcholines [25] . Furthermore, the fragmentation in the glycerol backbone and release of the fatty acyl substituents enabled the identification of individual species of phospholipids, as previously described [26] . 
Metabolic pathway analysis
Metabolic pathway analysis was performed to identify and visualize the affected pathways in the APP/PS1 mice on the basis of potential biomarkers detected. For this purpose, the MetPA web tool was employed (http://metpa.metabolomics.ca), which conducts pathway analysis through pathway enrichment analysis and pathway topological analysis [28] . In this work, we select the Mus musculus library and use the default 'Hypergeometric Test' and 'Relative-Betweenness Centrality' algorithms for pathway enrichment analysis and pathway topological analysis, respectively. In order to identify the most relevant pathways, the impact-value threshold calculated from pathway topology analysis was set to 0.1. 
Results
Metabolomic fingerprints obtained by direct infusion mass spectrometry analysis of the different brain regions from APP/PS1 and control mice were submitted to multivariate data analysis for samples classification. As a first exploratory step, principal component analysis (PCA) was applied for a preliminary evaluation of data quality. A good clustering of quality control samples was observed in the scores plot (Fig. 1A , for cortex), indicative of stability during the analyses, without significant outliers according to the Hotelling T 2 -range plot. Then, partial least squares discriminant analysis (PLS-DA) was used in the same data set to sharpen the separation between groups. Scores plot displayed a clear separation between samples of transgenic (TG) and control (WT) mice, as shown in Fig. 1B (for cortex). In addition, QC samples were predicted in the model and appeared clustered in the center of the scores plot, as expected since they were prepared by pooling equal volumes of individual samples. Moreover, statistical parameters confirmed the quality of these models in terms of class separation and predictive power, considering all brain regions analyzed (Table 1 ). In addition, the validation plots from the permutation tests (not shown) demonstrated the validity of this discrimination given that Q 2 regression showed a negative intercept and R 2 values of permuted models were lower than the R 2 value of the original one, indicating that the models were not overfitted.
Metabolites that contributed significantly to the separation of groups (VIP values higher than 1.5) were identified by MS/MS experiments. In Tables 2-4 are listed these potential markers arranged in different biochemical categories, with the ions detected in MS/MS experiments, the fold change (TG/WT ratio), p-value and VIP for each brain region. As can be observed, major changes were found in different classes of lipids including phospholipids and lysophospholipids (Table 2) , acylcarnitines (Table 3) , fatty acids and sterols (Table 4 ), but other low molecular weight metabolites were also perturbed ( Table 4) . Most of these metabolomic Table 1 Statistical parameters of PLS-DA models for hippocampus (HIP), cortex (CTX), cerebellum (CB), and olfactory bulbs (OB). A: number of latent components; alterations were observed in hippocampus and cortex, indicating that these are the most affected brain regions in APP/PS1 mice, but several impairments were also present in cerebellum and olfactory bulbs. Moreover, pathway analysis allowed the identification of altered biochemical pathways associated with these metabolic abnormalities, revealing important impairments in metabolism of lipids, amino acids and nucleotides (Fig. 2) .
Discussion
The potential of direct infusion mass spectrometry (DIMS) for metabolomic screening has been recently demonstrated in several studies using serum and plasma samples [29] [30] [31] [32] [33] [34] , due to its wide metabolome coverage and fast analysis. In the present work, this approach was employed for the characterization of regional metabolic abnormalities in brain of the APP/PS1 mice, a transgenic model of Alzheimer's disease. Major differences were observed in cortex and hippocampus, but these impairments also affected other regions such as cerebellum and olfactory bulbs. Furthermore, it is also noteworthy the great number of discriminant metabolites detected with this high-throughput tool compared with previous studies based on NMR [11] [12] [13] , facilitating the elucidation of potential mechanisms underlying to pathology.
The most important findings could be related to an abnormal metabolism of fatty acids, leading to the accumulation of free species principally in hippocampus and cortex (Table 4 ). This increase might be associated with an accelerated degradation of neural membrane lipids as well as impaired utilization of free fatty acids by ␤-oxidation, as revealed alterations observed in different classes of phospholipids, acylcarnitines and related compounds (Tables 2-4). Abnormal metabolism of membrane phospholipids caused by over-activated phospholipases activity, principally phospholipase A 2 (PLA 2 ), has been traditionally described as a key hallmark in the development of Alzheimer's disease [35] . Hydrolysis of the ester bonds from phospholipids by the action of PLA 2 produces the liberation of free fatty acids and lysophospholipids that may ultimately accumulate in brain, in agreement with results presented in Tables 2 and 4 . Furthermore, different byproducts resulting from degradation of phospholipids were also elevated, including glycerophosphocholine, phosphocholine, choline, as well as the final product of this degradation process, glycerol-3-phosphate, indicating an enhanced hydrolysis of brain phosphatidylcholines in accordance with previous studies [36] . The same trend was observed for glycerophosphoinositol, which denotes that catabolic stimulation of phospholipids metabolism is not only produced in choline-containing compounds, but also occurs in other families of compounds such as phosphatidylinositols. Moreover, the release of polyunsaturated fatty acids (PUFA) from the hydrolysis of these phospholipids by PLA 2 and subsequent oxidation can explain the elevation of different eicosanoids in brain samples, such as hydroxy-eicosapentaenoic (HEPE) and hydroxy-eicosatetraenoic (HETE) acids (Table 4) , which are important lipid mediators closely associated with neuronal pathways involved in AD neurobiology [37] . On the other hand, more confusing results were observed when specific changes in individual phospholipids are considered (Table 2) . Alterations in phospholipids levels depended on the type of fatty acid linked to the molecular moiety, as recently described for human AD where membrane destabilization processes were associated with imbalances in the levels of saturated/unsaturated fatty acids contained in the structure of phospholipids [33] . Thereby, major changes observed in this study corresponded to reduced levels of PUFA-containing phospholipids, principally phospatidylcholines (PC) and inositols (PI) containing docosahexaenoic acid (DHA), and most phosphatidylethanolamines (PE) and plasmenylethanolamines (PPE), which is in accordance with previous studies in brain from transgenic mice of AD [38] [39] [40] . However, a parallel accumulation of specific compounds was also observed in phospholipids derived from docosapentaenoic and docosatetraenoic acids, as well as different stearoyl-arachidonoyl-phospholipids, not previously described to our knowledge. In first place, elevated content of docosapentaenoic and docosatetraenoic acids in the brain phospholipid pool may be correlated to peroxisomal dysfunction, given that they are intermediates for the biosynthesis of long chain polyunsaturated fatty acids such as DHA in peroxisomes. In this 
2.27
Abbreviations: LPE: lysophosphoethanolamine; LPC: lysophosphocholine; LPI: lysophosphoinositol; PE: phosphoethanolamine; PPE: plasmenylethanolamine; PC: phosphocholine; PS: phosphoserine; PI: phosphoinositol, P: positive mode; N: negative mode. sense, substantial peroxisome-related alterations have been previously described in AD brains, inducing the accumulation of very long chain fatty acids and deficits of plasmalogens and DHA [41] . Moreover, the increase of stearoyl-arachidonoyl-phospholipids (PC, PE, PI) denotes a profound membrane remodeling in the APP/PS1 mice as it is one of the most abundant species on the brain [42] , being cortex the most affected region. Therefore, alterations in phospholipids metabolism appears to have a multifactorial origin involving over-activation of phospholipases, peroxisomal dysfunction and abnormal fatty acid composition of phospholipids. Alternatively, deficits for most acylcarnitines in brain of the APP/PS1 mice (Table 3 ) might indicate a perturbed lipid metabolism, also contributing to the accumulation of free fatty acids. Lower levels of l-carnitine in brain (Table 3) have been previously reported in AD patients [43] , together with altered expression of several related enzymes such as decreased carnitine acetyltransferase activity [44] , or over-expressed hydroxyacyl-coenzyme A dehydrogenase (HADHA) [45] and short chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD) [46] . These results suggest a perturbed transport of fatty acids into the mitochondria for ␤-oxidation, which together with the increased rate of phospholipids degradation finally induces the accumulation of free fatty acids. Conversely, levels of propionyl-carnitine and propionic acid were increased in brain samples, indicating a specific disturbance in propionate metabolism. In this sense, Cuadrado-Tejedor et al. [47] recently found a differential expression of propionyl-CoA carboxylase in hippocampus of the Tg2576 mouse, which could cause the propionic acidemia observed in this study. This abnormal catabolism of lipids was accompanied by other impairments in energy metabolism, regarding increased brain levels of pyruvate and alanine (Table 4) . Elevation of pyruvate level in AD brain has been previously associated with a decreased rate of carbohydrate utilization by the neuron in response to drastic reductions in the activities of enzymes involved in pyruvate oxidation [48] . In the same way, increased concentration of alanine, produced in the body from the conversion of pyruvate, may also indicate a change in the carbohydrate metabolism of the brain [10, 11, 17] . Taking all this into account, we can conclude that several cellular impairments occur in brain of the APP/PS1 mice in direct relation to the accumulation of free fatty acids, involving multiple alterations in phospholipids metabolism and different energetic pathways, as schematized in Fig. 3A .
There is also growing evidence for the involvement of nucleotide metabolism in different neurodegenerative mechanisms in Alzheimer's disease, in accordance with alterations found for numerous purine and pyrimidine metabolites in all brain regions of the APP/PS1 mice (Table 4) . Elevated adenosine monophosphate deaminase activity has been identified in AD brains, provoking accelerated degradation of AMP and overproduction of ammonia leading to hyperammonemia [49] . In addition, the decrease of AMP levels may have important consequences in cellular energy homeostasis, given that it plays a central role in glucose and lipid metabolism through the AMP-activated protein kinase (AMPK), which is known to be decreased in AD brain [50] . Moreover, purinergic signaling also appears to play a role in the development of AD, with an up-regulation of adenosine receptors in the frontal cortex of affected brains [51] , as well as a redistribution of these receptors, with a higher activity in neurons affected by ␤ amyloid deposition or hyperphosphorilation of protein [52] . Dysregulation of pyrimidine metabolism, with decreased uridine monophosphate and increased uracil (Table 4) , could reflect reduced synaptic plasticity and neuronal deficits due to decreased synthesis of phosphatidylcholines via the Kennedy cycle [53] . Finally, several studies have also implicated oxidative stress in abnormal metabolism of purines and pyrimidines in AD, demonstrating an increase of oxidized DNA bases in brain [54, 55] , such as 8-hydroxyadenine, 8-hydroxyguanine or FAPy-adenine, as in our metabolomic screening test. Therefore, metabolism of purines and pyrimidines highlights as a candidate pathway for the search of potential markers of pathological processes occurring in the APP/PS1 transgenic mice (Fig. 3B) .
Decreased levels of cholesterol, cholesterol sulfate, deoxycholic (DCA) and taurodeoxycholic (TCA) acids were also found in hippocampus and cortex (Table 4) . It has been previously demonstrated that the APP/PS1 transgenic mice exhibit altered cholesterol metabolism, resulting in reduced content of cholesterol in brain [38, 56] and generating serious alterations of the physicochemical structure of lipid rafts. The same trend was observed for cholesterol sulfate, a component of cell membranes where it plays a stabilizing role [57] , not previously described to our knowledge in AD research. Finally, reductions of brain deoxycholic and taurocholic acids (or isomers) could be behind different neuropathological conditions, given that ursodeoxycholic acid (UDCA) and tauroursodeoxycholic acid (TUDCA) have been demonstrated to be potent inhibitors of apoptosis [58] , and they present neuroprotective action against amyloid deposition [59] . Other potential markers found by metabolomic fingerprinting of brain tissues could be related to failures in neurotransmitter systems, including deficits in tyrosine, dopamine and aspartate, as well as increased N1-acetylspermidine (Table 4) . Dopamine is a neurotransmitter derived from the amino acid tyrosine, commonly linked to Parkinson's disease. However, disturbances in the biosynthesis of monoaminergic neurotransmitters and their precursors have been also reported in AD subjects [60, 61] . On the other hand, aspartate is an excitatory neurotransmitter that, similarly to glutamate, usually presents lower concentrations in AD brain [18] and cerebrospinal fluid [62] . Finally, amyloid beta deposition is known to up-regulate polyamine metabolism in Alzheimer's disease by increasing ornithine decarboxylase activity and polyamine uptake [63] , leading to altered levels of polyamines in brain. In this context, Inoue et al. [64] found an abnormal increase of N1-acetylspermidine and other polyamines in AD brains, which was associated with N-methyl-d-aspartate (NMDA) receptor excitotoxicity, confirming our metabolomic findings. The significant reduction in urea levels (Table 4) pointed to a perturbation of the urea cycle, responsible for controlling ammonia concentrations in the organism. In Alzheimer's disease, the alteration of this pathway has been previously demonstrated on the basis of altered levels of expression in different enzymes and the corresponding genes [65] . To conclude changes observed in homocarnosine and glutathione, important antioxidants involved in the defense of the central nervous system, could be related to oxidative damage in brain. Reduced levels of homocarnosine (Table 4) have been previously described in brains of patients with Alzheimer's disease [66] , as well as other related dipeptides such as carnosine [61] . On the other hand, levels of glutathione were surprisingly increased in different brain regions of the APP/PS1 mice (Table 4) , although most previous studies reported reduced content of this antioxidant during AD development in both humans and transgenic models [8, 67] . However, Adams et al. [68] also described an analogous increase in AD brain, proposing that a compensatory elevation of glutathione must occur against cellular damage produced by oxidative stress.
Conclusions
The potential of direct infusion mass spectrometry for metabolomic analysis of brain samples has been demonstrated in this study, in terms of non-targeted metabolite coverage, rapidity of analysis and, consequently, high-throughput screening capability. This approach was employed for the investigation of regional metabolic abnormalities in brain of transgenic APP/PS1 mice of Alzheimer's disease compared with wild-type control mice. Major differences were observed in hippocampus and cortex, primary brain targets in Alzheimer's disease, but cerebellum and olfactory bulbs were also affected to a lesser extent. Furthermore, these metabolic alterations could be linked to different pathways associated with pathological mechanisms occurring in the APP/PS1 mice, such as impaired metabolism of fatty acids and phospholipids, bioenergetic failures, altered metabolism of purines and pyrimidines, changes in neurotransmission or oxidative stress. Therefore, these results highlight the importance of transgenic models for the study of underlying pathological mechanisms in AD brain, a sample not readily accessible in human investigations.
